Citius Pharmaceuticals heads into its May 19 earnings report carrying one of the most charged short setups in the small-cap pharma space.
Short sellers have been piling in. Short interest as a percentage of free float has jumped from roughly 15% in mid-April to just over 20% today — a 26% week-on-week increase in shares short and nearly 29% over the month. The ORTEX short score now reads 90.2, placing CTXR in the extreme decile of short conviction across the entire universe. The borrow market reflects that pressure: cost to borrow has more than doubled over the past month to nearly 50% annualised, and availability has tightened sharply — dropping from above 100% in early May to around 48% now. That tightening means the pool of lendable shares is shrinking relative to what's already been borrowed. The 52-week low in availability reached 1%, so there is historical precedent for a further squeeze on borrow supply.
Options positioning adds another dimension — though not the defensive one you'd expect. The put/call ratio spiked to 0.085 on May 18, more than four standard deviations above its 20-day mean of 0.030. That sounds alarming, but in context the absolute PCR level remains very low, and the ratio has sat in a tight range near its 52-week floor for most of the past month. The sudden jump may reflect thin options markets rather than a true directional bet. What the options market has consistently told this story is that call-side interest has dominated — bulls have been buying upside, not protection.
The analyst debate is skewed bullish but sparse. HC Wainwright initiated coverage yesterday with a Buy and a $4 target. D. Boral Capital holds a $6 Buy, though that target was trimmed from $9 last June. With the stock trading near $0.70, both targets imply enormous implied upside — a gap that reflects either deep conviction in the LYMPHIR oncology franchise or, more cautiously, the inherent speculative risk of a single-asset pre-revenue biotech. The bull case centres on LYMPHIR's 86% overall response rate in a heavily pretreated population and a recent licensing deal with Er-Kim that opens 19 non-US markets. Bears point to widening losses, no meaningful revenue diversification, and a prolonged regulatory and commercialisation timeline that continues to drain cash.
Earnings history offers a consistent pattern: the stock fell approximately 6.7-6.9% on the day of each of the last three prints. The five-day window was more mixed — a sharp 10.6% decline after the February 2026 event, a near-flat recovery after the prior one. The print today is less a test of whether LYMPHIR works clinically and more a test of whether Citius can show any credible path toward revenue, at a moment when short sellers are the most aggressively positioned they have been all year.
See the live data behind this article on ORTEX.
Open CTXR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
